Treatment for diabetes in patients inappropriate for metformin therapy

  • US 9,486,526 B2
  • Filed: 06/03/2014
  • Issued: 11/08/2016
  • Est. Priority Date: 08/06/2008
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating and/or preventing type 2 diabetes mellitus in a patient having moderate or severe chronic renal impairment or end-stage renal disease comprising orally administering to the patient a DPP-4 inhibitor, which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine or a pharmaceutically acceptable salt thereof, wherein said DPP-4 inhibitor is administered in an oral dose of 5 mg per day to said patient, wherein metformin therapy for said patient is ineligible due to contraindication against metformin.

View all claims

    Thank you for your feedback